Gene therapy: how much will it cost patients?
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
The FDA’s proposed changes to device regulation are thin on detail
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
For drug treatment decisions machine learning must be more than a black box
The industry has its work cut out to rebuild trust in the tech following doubts about one pioneer, IBM Watson.
How machines could mine forgotten data
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Big pharma piles into machine learning, but what will it get out of it?
Big pharma is using machine learning to improve the drug development process – but can the tech live up to the hype?
The million-dollar question hanging over US research funding law
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?
The $100,000 problem gene therapy companies would rather not mention
The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.
Reasons to be cautious about new haemophilia therapies
Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.
Canada’s medical cannabis ambition no laughing matter
Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.
